Vertex Pharmaceuticals (MA) (VRTX) Joins GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) in Testing Hepatitis C Combos  
11/1/2012 7:00:27 AM

Vertex Pharmaceuticals Inc. (VRTX), maker of the hepatitis C drug Incivek, said it agreed to test one of its experimental therapies for the disease with other drugs from Johnson & Johnson (JNJ) and GlaxoSmithKline Plc. (GSK)

The drug, VX-135, will be tested with J&J’s simeprevir and Glaxo’s GSK2336805 in 12-week trials to determine whether the combinations help rid patients of the virus, Cambridge, Massachusetts-based Vertex said in two statements today. The companies will split development costs with Vertex.